BACKGROUND: Mutations in PALB2 predispose to breast cancer, but the effect on prognosis of carrying a PALB2 mutation has not been ascertained. We aimed to estimate the odds ratio for breast cancer in women with an inherited mutation in PALB2 and 10-year survival after breast cancer in patients who carry a PALB2 mutation. METHODS: Between 1996 and 2012, patients with invasive breast cancer were recruited prospectively from 18 hospitals in Poland and genotyped for two deleterious mutations in PALB2 (509_510delGA and 172_175delTTGT). A control group of 4702 women without cancer was recruited for comparison. The primary endpoint was death from any cause, as determined by medical records from the Polish Ministry of the Interior and Administration. In patients with breast cancer, 10-year survival of carriers of a PALB2 mutation was calculated and compared with that of non-carriers. FINDINGS: 17 900 women with breast cancer were invited to participate, of whom 12 529 were genotyped successfully. A PALB2 mutation was present in 116 (0·93%, 95% CI 0·76-1·09) of 12 529 patients and in ten (0·21%, 0·08-0·34) of 4702 controls (odds ratio 4·39, 95% CI 2·30-8·37; p<0·0001). 10-year survival for women with breast cancer and a PALB2 mutation was 48·0% (95% CI 36·5-63·2), compared with 74·7% (73·5-75·8) for patients with breast cancer without a mutation (adjusted hazard ratio for death 2·27, 95% CI 1·64-3·15; p<0·0001). INTERPRETATION: Women with a PALB2 mutation face an increased risk of breast cancer and might be at a higher risk of death from breast cancer compared with non-carriers. Increased surveillance should be offered to unaffected women who carry a PALB2 mutation. FUNDING: Polish National Science Centre.
BACKGROUND: Mutations in PALB2 predispose to breast cancer, but the effect on prognosis of carrying a PALB2 mutation has not been ascertained. We aimed to estimate the odds ratio for breast cancer in women with an inherited mutation in PALB2 and 10-year survival after breast cancer in patients who carry a PALB2 mutation. METHODS: Between 1996 and 2012, patients with invasive breast cancer were recruited prospectively from 18 hospitals in Poland and genotyped for two deleterious mutations in PALB2 (509_510delGA and 172_175delTTGT). A control group of 4702 women without cancer was recruited for comparison. The primary endpoint was death from any cause, as determined by medical records from the Polish Ministry of the Interior and Administration. In patients with breast cancer, 10-year survival of carriers of a PALB2 mutation was calculated and compared with that of non-carriers. FINDINGS: 17 900 women with breast cancer were invited to participate, of whom 12 529 were genotyped successfully. A PALB2 mutation was present in 116 (0·93%, 95% CI 0·76-1·09) of 12 529 patients and in ten (0·21%, 0·08-0·34) of 4702 controls (odds ratio 4·39, 95% CI 2·30-8·37; p<0·0001). 10-year survival for women with breast cancer and a PALB2 mutation was 48·0% (95% CI 36·5-63·2), compared with 74·7% (73·5-75·8) for patients with breast cancer without a mutation (adjusted hazard ratio for death 2·27, 95% CI 1·64-3·15; p<0·0001). INTERPRETATION:Women with a PALB2 mutation face an increased risk of breast cancer and might be at a higher risk of death from breast cancer compared with non-carriers. Increased surveillance should be offered to unaffected women who carry a PALB2 mutation. FUNDING: Polish National Science Centre.
Authors: Eric Hahnen; Jan Hauke; Christoph Engel; Guido Neidhardt; Kerstin Rhiem; Rita K Schmutzler Journal: Breast Care (Basel) Date: 2017-02-24 Impact factor: 2.860
Authors: Joanne Kotsopoulos; Victoria Sopik; Barry Rosen; Isabel Fan; John R McLaughlin; Harvey Risch; Ping Sun; Steven A Narod; Mohammad R Akbari Journal: Fam Cancer Date: 2017-01 Impact factor: 2.375
Authors: Rebecca H Johnson; Carey K Anders; Jennifer K Litton; Kathryn J Ruddy; Archie Bleyer Journal: Pediatr Blood Cancer Date: 2018-08-28 Impact factor: 3.167
Authors: Chunling Hu; Steven N Hart; Rohan Gnanaolivu; Hongyan Huang; Kun Y Lee; Jie Na; Chi Gao; Jenna Lilyquist; Siddhartha Yadav; Nicholas J Boddicker; Raed Samara; Josh Klebba; Christine B Ambrosone; Hoda Anton-Culver; Paul Auer; Elisa V Bandera; Leslie Bernstein; Kimberly A Bertrand; Elizabeth S Burnside; Brian D Carter; Heather Eliassen; Susan M Gapstur; Mia Gaudet; Christopher Haiman; James M Hodge; David J Hunter; Eric J Jacobs; Esther M John; Charles Kooperberg; Allison W Kurian; Loic Le Marchand; Sara Lindstroem; Tricia Lindstrom; Huiyan Ma; Susan Neuhausen; Polly A Newcomb; Katie M O'Brien; Janet E Olson; Irene M Ong; Tuya Pal; Julie R Palmer; Alpa V Patel; Sonya Reid; Lynn Rosenberg; Dale P Sandler; Christopher Scott; Rulla Tamimi; Jack A Taylor; Amy Trentham-Dietz; Celine M Vachon; Clarice Weinberg; Song Yao; Argyrios Ziogas; Jeffrey N Weitzel; David E Goldgar; Susan M Domchek; Katherine L Nathanson; Peter Kraft; Eric C Polley; Fergus J Couch Journal: N Engl J Med Date: 2021-01-20 Impact factor: 91.245
Authors: Maciej Jóźwik; Renata Posmyk; Marcin Jóźwik; Andrzej Semczuk; Magdalena Gogiel-Shields; Marta Kuś-Słowińska; Magdalena Garbowicz; Mark Klukowski; Jacek Wojciechowicz Journal: Cancer Biol Ther Date: 2018-07-03 Impact factor: 4.742
Authors: Nadine Tung; Nancy U Lin; John Kidd; Brian A Allen; Nanda Singh; Richard J Wenstrup; Anne-Renee Hartman; Eric P Winer; Judy E Garber Journal: J Clin Oncol Date: 2016-03-14 Impact factor: 44.544
Authors: Masaru Miyano; Rosalyn W Sayaman; Sundus F Shalabi; Parijat Senapati; Jennifer C Lopez; Brittany Lynn Angarola; Stefan Hinz; Arrianna Zirbes; Olga Anczukow; Lisa D Yee; Mina S Sedrak; Martha R Stampfer; Victoria L Seewaldt; Mark A LaBarge Journal: Cancer Prev Res (Phila) Date: 2021-06-17